



DAFTAR PUSTAKA

- Abizaid, A. 2007. Sirolimus-eluting coronary stents: a review. *Vascular Health and Risk Management*, 3(2), 191–201.
- Acharya, G. and Park, K. 2006. Mechanisms of controlled drug release from drug-eluting stents, *Adv. Drug Deliv. Rev.*, 58:387–401.
- Ahanchi S. S., Tsihlis N. D., and Kibbe M. R. 2007. The Role of Nitric Oxide in the Pathophysiology of Intimal Hyperplasia. *J. Vasc. Surg.* 45, A64–A73.
- Akin I., Scheneider H., Ince H., Kische S., Rehders T. C., Chatterje T., and Nienaber C. A. 2011. Second- and Third- Generation Drug Eluting Coronary Stents: Progress and Safety. *Herz* 36: 190-196.
- Attele A.S., Wu J.A., and Yuan C.-S. 1999. Ginseng Pharmacology: Multiple constituents and Multiple actions. *Biochem Pharmacol.* Vol.58:1685–1693.
- Bhatia V., Bhatia R., and Dhindsa M. 2004. Drug-Eluting Stents: New Era and New Concerns. *Postgrad Med J* 80: 13-18.
- Bognár, E., R. György, T. Balázs, J. Dobránszky. 2008. Investigation of Drug Eluting Stents, *Materials Science Forum*, 589: 361-366.
- Carter, Andrew J., John R. Laird, Andrew Farb, William Kufs, Dale C. Wortham, Renu Virmani. 1994. Morphologic Characteristics of Lesion Formation and Time Course of Smooth Muscle Cell Proliferation in a Porcine Proliferative Restenosis Model. *Journal of the American College of Cardiology*, 24 (5): 1398-1405.
- Chang J.Y., Sehgal S. N., and Bansbach C. C. 1991. FK506 and rapamycin novel pharmacological probes of the immune response. *Trends Pharmacol Sci.* (12) :218–23.
- Chen H. W. and Huang H. C. 1998. Effect of Curcumin on Cell Cycle Progression and Apoptosis in Vascular Smooth Muscle Cells. *British Journal of Pharmacology*, 124; pp. 1029-1040.
- Chen, M.-C., Liang, H.-F., Chiu, Y.-L., Chang, Y., Wei, H.-J., & Sung, H.-W. 2005. A novel drug-eluting stent spray-coated with multi-layers of collagen and sirolimus. *Journal of Controlled Release*, 108(1), 178–189.
- Chen W., Habraken T. C. J., Hennink W. E., and Kok R. J. 2015. Polymer-Free



Drug-Eluting Stents: An Overview of Coating Strategies and Comparison with Polymer-Coated Drug-Eluting Stents. *Bioconjugate Chemistry*, 26 (7), 1277-1288.

Deconinck E., Sohier J., De Scheerder I., and Van den Mooter G. 2008. Pharmaceutical Aspects of Drug Eluting Stents. *J. Pharm. Sci.* 97(12): 5407-5060.

Dentaurum, 2011, remanium® star CL material data sheet, [internet] diunduh pada 10 November 2019, Tersedia pada: <https://www.dentaurum.de/eng/cocr-legierung-remanium-star-cl-23836.aspx>

Dibra A., Kastrati, A., Mehilli, J., Pache, J., von Oepen, R., Dirschinger, J., and Schomig, A. 2005. Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: A randomized double-blind controlled trial. *Catheterization and Cardiovascular Interventions*, 65 (3), 374-380.

Dinarvand, R., Mahmoodi, S., Farboud, E., Salehi, M., Atyabi, F., 2005, Preparation of gelatin microspheres containing lactic acid-effect of crosslinking on drug release. *Acta Pharmaceutica*, 55 : 57–67.

Douroumis D. and Onyesom I. 2011. Novel Coating Technologies of Drug Eluting Stents. University of Greenwich, School of Science, Medway Campus, Chatham Maritime, ME4 4TB, Kent, UK, d.douroumis@gre.ac.uk.

Ernst A. and Bulum J. 2014. New Generations of Drug-Eluting Stents A Brief Review. *EMJ Int Cardiol* 1: 100-106.

Finn A. V., Kolodgie F. D., Harnek J., Guerrero L. J., Acampado E., Tefera K., Skorija K et. al. 2005. Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus-or Paclitaxel-eluting Stents. *Circulation* 112: 270-278.

Gallo R., Padurean A., and Jayaraman T. 1999. Inhibition of Intimal Thickening after Balloon Angioplasty in Porcine Coronary arteries by Targeting Regulators of the Cell Cycle. *Circulation*. (99):2164–70.

Gocke, C., Grabow, N., Schultze, C., Sternberg, K., Schmidt, W., and Schmitz, K. P. 2008. Coating Homogeneity in the Manufacture of Drug Eluting Stents. *4th European Confrence of the International Federation for Medical and Biological Engineering*, p. 2241-2246. Belgium: Springer Verlag.

Grabow N., Martin D. P., Schmitz K-P., and Stenberg K. 2010. Absorbable Polymer Stent Technologies for Vascular Regeneration. *J Chem Tech Biotechnol* 85: 744-751.



- Groth C. G., Bachman L., and Morales J. M. 1999. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. *Transplantation*. (67):1036–42.
- Grube E., Gerckens U., Muller R., and Bullesfeld L. 2002. Drug Eluting Stents: Initial Experiences, *Z. Kardiol*. 91 (Suppl. 3): 44-48.
- Hafner B. 2007. Scanning Electron Microscopy Primer. Characterization Facility, University of Minnesota-Twin Cities.
- Han C-M., Park K-S., and Joung Y. K. 2017. Review: Recent Alternative Approaches of Vascular Drug-Eluting Stents. *Journal of Pharmaceutical Investigation*.
- Hasegawa H. 2004. Proof of The Mysterious Efficacy of Ginseng: Basic and Clinical Trials: Metabolic Activation of Ginsenoside: Deglycosylation by Intestinal Bacteria and Esterification with Fatty Acid. *J Pharmacol Sci*. Vol. 95:153–157.
- He J. and Li Y.-L. 2015. Ginsenoside Rg1 Downregulates The Shear Stress Induced MCP-1 Expression by Inhibiting MAPK Signaling Pathway. *Am. J. Chin. Med.* 43, 305-317.
- Herliansyah M. K., Iman K. A., Tontowi A. E. dan Siswomihardjo W. 2016. Potential of Curcumin as Antiproliferative Drug for Developing Drug Eluting Stent: A Brief Review. Yogyakarta.
- Ho, M.-Y., Chen, C.-C., Wang, C.-Y., Chang, S.-H., Hsieh, M.-J., Lee, C.-H., Wu, V. and Hsieh, I.-C. 2016. The Development of Coronary Artery Stents: From Bare-Metal to Bio-Resorbable Types, *Metals*, 6(7), p. 168.
- ISO 4287:1997 (E/F). Geometrical Product Specifications (GPS)-Surface Texture: Profile Method-Terms, Definitions and Surface Texture Parameters.
- Joner M., Finn A. V., Farb A., Mont E. K., Kolodgie F. D., Ladich E., Kutys R. *et. al.* 2006. Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombosis Risk. *J Am Coll Cardiol* 48: 193-202.
- Jorge C. and Dubois C. 2015. Clinical Utility of Platinum Chromium Bare Metal Stents in Coronary Heart Disease. *Med Devices (Auckl)* 8: 359-367.
- Kavanagh C. A., Rochev Y. A., Gallagher W. M., Dawson K. A., and Keenan A. K., 2004. Local Drug Delivery in Restenosis Injury: Thermoresponsive Co-Polymers as Potential Drug Delivery Systems. *Pharmacol. Ther.* 102



(1): 1-15.

- Kim, J. H., Yi, Y.-S., Kim, M.-Y., and Cho, J. Y. 2017. Role of Ginsenosides, The Main Active Components of Panax Ginseng, in Inflammatory Responses and Diseases. *Journal of Ginseng Research*, 41(4), 435–443.
- Kuntz R. E., Gibson, C. M., Nobuyoshi M., and Baim D. S. 1993. Generalized Model of Restenosis after Conventional Balloon Angioplasty, Stenting, and Directional Atherectomy. *J Am Coll Cardiol* ; 21: 15-25
- Lee C. H and Kim J. H. 2014. A Review on the Medicinal Potentials of Ginseng and Ginsenosides on Cardiovascular Diseases. *J. Ginseng Res.* 38, 161–6.
- Levesque J., Dube D., Fiset M., and Mantovani D. 2004. Materials and Properties for Coronary Stents. *Advanced Materials & Processes*, vol. 162, no. 9, pp. 45-48.
- Liu V. W and Huang P. L. 2008. Cardiovascular Roles of Nitric Oxide: A review of Insights from Nitric Oxide Synthase Gene Disrupted Mice. *Cardiovasc. Res.* 77, 19–29.
- Ma L., Liu H., Xie Z., Yang S., Xu W., Hou J., and Yu B. 2014. Ginsenoside Rb3 Protects Cardiomyocytes against Ischemia-Reperfusion Injury via the Inhibition of JNK-Mediated NF- κ B Pathway: A Mouse Cardiomyocyte Model. *PLoS ONE* 9, e103628.
- Mahfouz M. M., Zhou S. Q., and Kummerow F. A. 2009. Curcumin Prevents The Oxidation and Lipid Modification of LDL and its Inhibition of Prostacyclin Generation by Endothelial Cells in Culture. *Prostaglandins Other Lipid Mediat.*; 90(1-2): 13–20.
- Majeed M., Badmaev V., Shirakumar U., and Rajendrar R. 1995. Curcuminoids Antioxidant Phytonutrients. 3-80. *Pis Catway, NJ.: Nutri Science Publisher Inc.*
- Mazinani, A. 2014. Surface Modification Treatment of cardiovascular Ring. Milan: Department of Chemistry, Materials and Chemical Engineering, Politecnico Di Milano.
- Mizwan Z., Lukman S. K., Majid F. A. A., Loke M. F., Saidin and Hermawan H. 2016. Drug-eluting coating of ginsenoside Rg1 and Re incorporated poly(lactic-co-glycolic acid) on stainless steel 316L: Physicochemical and drug release analyses. *Int J Pharm* 515 (1-2), pp. 460-466.
- Nag, S. A., Qin J. J., Wang W., Wang M. H., Wang H., and Zhang R. 2012. Ginsenosides as Anticancer Agents: In Vitro and In Vivo Activities,



Structure-Activity Relationships, and Molecular Mechanisms of Action. *Front. Pharmacol.* 3, 1–18.

Nam S. H., Nam H. Y., Joo J. R., Back I. S., and Park J. S. 2007. Curcumin-loaded PLGA Nanoparticles Coating onto Metal Stent by Electrophoretic Deposition Techniques. *Bull Korean Chem Soc* 28: 397-402.

Nazneen F., Gregoire H., Damien W. M. A., Noel C., Pasquale B., Paul G., and Michael T. 2012. Surface chemical and physical modification in stent technology for the treatment of coronary artery disease. *Journal of Biomedical Material Research Part B*, 100 B:1989-2014.

Nguyen K. T., Shaikh N., Shukla K. P., Su S. H., Eberhart R. C., and Tang L. 2004. Molecular Responses of vascular Smooth Muscle Cells and Phagocytes to Curcumin-eluting Bioresorbable Stent Materials. *Biomaterials* 25 (23): 5333-5346.

Nugroho, A. B. 2005. Strategi jitu memilih metode Statistik Penelitian Dengan SPSS. Yogyakarta: Andi Offset.

Nurtamin T. 2014. Potensi Curcumin untuk Mencegah Aterosklerosis. *CDK-219*: 41(8).

Oberg, Erik and Franklin, D. Jones. 1996. Machinery's Handbook 25th Edition. *Industrial Press, Inc.* New York.

Pache J., Kastrati A., Mehilli J., Schühlen H., Dotzer F., Hausleiter J., Fleckenstein M., Neumann F.J., Sattelberger U., and Schmitt C. 2003. Intracoronary stenting angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. *J. Am. Coll. Cardiol.* 2003, 41, 1283–1288.

Pan C. J., Tang, J.J., Weng, Y.J., Wang, J., Huang, N., 2006, Preparation, characterization and anticoagulation of curcumin-eluting controlled biodegradable coating stents. *Journal of Controlled Release*, 116:42–49.

Pan C. J., Tang, J. J., Shao Z. Y., Wang J., and Huang N. 2007. Improved Blood Compatibility of Rapamycin-Eluting Stent by Incorporating Curcumin. *Colloids and Surfaces B*, 59, pp. 877-890.

Pendyala L. K., Yin X., Li J., Chen P., Chronos N., and Hou D. 2009. The First Generation Drug Eluting Stents and Coronary Endothelial Dysfunction. *JACC Cardiovasc. Interv.* 2(12):1169-1177.

Pendurthi U. R., William J. T., and Rao L. V. 1997. Inhibition of Tissue Factor Gene Activation in Cultured Endothelial Cells by Curcumin. Suppression of Activation of Transcription Factors Egr-1, AP-1, and NF-kappa B.



Arterioscles Thromb Vasc Biol.;12:3406–13.

Poncin P., Millet C., Chevy J. and Proft J. 2004. Comparing and Optimizing Co-Cr Tubing for Stent Applications. Material & Processes for Medical Devices Conference. *ASM International 2004*.

Poncin P. and Proft J. 2004. Proceedings of the 2003 Materials & Processes for Medical Devices Conference. *ASM International 2004*.

Poston R. S., Billingham M., and Hoyt E. G. 1999. Rapamycin Reverses Chronic Graft Vascular Disease in a Novel Cardiac Allograft Model. *Circulation*. (100):67–74.

Puranik A. S., Dawson E. R., and Peppas N. A. 2013. Recent Advances in Drug Eluting Stents. *Int J Pharm*. 30; 441(1-2), pp: 665-679.

Rahardjo S., 2016, *Cara Uji Paired Sample T-Test dan Interpretasi dengan SPSS*, [Internet], diunduh pada 1 November 2019, Tersedia pada: <https://www.spssindonesia.com/2016/08/cara-uji-paired-sample-t-test-dan.html>

Rastogi S., Rizwani W., Joshi B., Kunigal S., and Chellappan S. P. 2012. TNF- α Response of Vascular Endothelial and Vascular Smooth Muscle Cells Involve Differential Utilization of ASK1 Kinase and p73. *Cell Death Differ*. 19, 274–83.

Raval, A., Choubey, A., Engineer, C., and Kothwala, D. 2005. Surface Conditioning of 316LVM Slotted Tube Cardiovascular Rings. *Journal of Biomaterial Applications*, 19(3), 197-213.

Rensing B. J., Vos J., Smits P. C., Foley D. P., van den Brand M. J., van der Giessen W. J., de Feijter P. J. et. al. 2001. Coronary Restenosis Elimination with A Sirolimus Eluting Stent: First European Human Experience with 6-Month Angiographic and Intravascular Ultrasonic follow-up. *Eur Heart J* 22: 2125-2130.

Shah B. H. Nawaz Z., Pertani S. A., Roomi A., Mahmood H., Saeed S. A., and Gilani A. H. 1999. Inhibitory Effect of Curcumin, A Food Spice from Turmeric, on Platelet-activating Factor- and Arachidonic Acid-mediated Platelet Aggregation through Inhibition of Thromboxane Formation and Ca²⁺ Signaling. *Biochem Pharmacol* 58: 1167-1172.

Shaikh M., Kichenadasse G., Choudhury N. R., Butler R., and Garg S. 2013. Non-vascular Drug Eluting Stents as Localized Controlled Drug Delivery Platform: Preclinical and Clinical Experience. *J Control Release* 172: 105-117.



- Sojitra, P. 2010. Electropolishing of 316 L Stainless Steel Cardiovascular Ring : An Investigation of Material Removal, Surface Roughness and Corrosion Behaviour. *Trends Biometer*, 23(3), 115-121.
- Song J. F. And Verburger T. V. 2010. Surface Texture. *National Institute of Standards and Technology*, p. 334-345.
- Sousa J. E., Patrick W. S., and Marco A. C. 2003. New frontiers in cardiology, drug-eluting stents: part 1, *Circulation* 107:2274-2279.
- Srivastava R., Dikshit M., Srimal R. C., and Dhawan B. N. 1985. Antithrombotic Effect of Curcumin. *Thromb. Res* 40(3): 413-417.
- Stary H. C., Chandler A. B., Dinsmore R. E., Fuster V. Glagov S., Insull W. Jr., Rosenfeld M. E., Schwartz C. J., Wagner W. D., and Wissler R. W. 1995. A Definition of Advanced Types of Atherosclerotic Lesions and A Histological Classification of Atherosclerosis. *Circulation*; 92(5): 1355-74.
- Stone G. W., Moses J. W., Ellis S. G., Schofer J., Dawkins K. D., Morice M. C., Colombo A. et.al. 2007. Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. *N Engl J Med* 256: 998-1008.
- Sujatno A., R. Salam, Bandriyana, A. Dimiyati. 2015. Studi Scanning Electron Microscopy (SEM) untuk Karakterisasi Proses Oksidasi Paduan Zirkonium, *Jurnal Forum Nuklir (JFN)*, 9 (2) : 44-50.
- Sun Y., Liu Y., and Chen K. 2016. Roles and Mechanisms of Ginsenoside in Cardiovascular Diseases: Progress and Perspectives. *Sci. China Life Sc.* 59, 292-298.
- Suryawan, D. 2017. Desain, Pemodelan, dan Pembuatan Prototype Ring Jantung Menggunakan Electrical Discharge Machining (EDM). Yogyakarta: Fakultas Teknik UGM.
- Tamburino C. and Capodanno D. 2009. Evolution of Stents: Past, Present and Future. *Expert. Rev. Cardiovasc. Ther.* 7(5): 443-446.
- Topol E. J. 2001. Acute Coronary Syndromes: Second Edition Revised and Expanded. *Marcel Dekker, Inc.* New York.
- Van der Hoeven B. L., Pires N. M., Warda H. M., Oemrawsingh P. V., van Vlijmen B. J., Quax P. H., Schalij M. J., van der Wall E. E., and Jukema J. W. 2005. Drug Eluting Stents: Results, Promises, and Problems. *Int. J. Cardiol.* 99 (1): 9-17.



- Vo, Tuoi T. N., Sarah Morgan, Christopher McCormick, Sean McGinty, Sean McKee, Martin Meere. 2018. Modelling drug release from polymer-free coronary stents with microporous surfaces. *International Journal of Pharmaceutics* 544: 392-401
- Wang J., L. Li, A. C. Roc, D. C. Alsop, K. Tang, N. S. Butler, M. D. Schnall and J. A. Detre. 2003. *Magnetic Resonance Imaging*. Vol 49 (5): 972-976.
- Wang X., Venkatraman S. S., Boey F.Y., Loo J.S., and Tan L.P. 2006. Controlled release of sirolimus from a multilayered PLGA stent matrix. *Biomaterials* 27(32):5588-95.
- Wiktor D. M. 1989. Intravascular radially expandable stent and method of implant. *US patent* 4,886,062.
- Wright C., Llanos G. H., Rakos R., and King K. 1999. Stent with local rapamycin delivery. *Patent* EP0950386 (A2).
- Wright C., Llanos G. H., Rakos R., and King K. 2001. Modified stent useful for delivery of drugs along stent strut. *US Patent* 6,273,913.
- Yun T.K. 2001. Brief Introduction of Panax Ginseng CA Meyer. *J Korean Med Sci*.16:S3.
- Zhang H. S and Wang S. Q. 2006. Ginsenoside Rg1 Inhibits Tumor Necrosis Factor- α (TNF- α)-induced Human Arterial Smooth Muscle Cells (HASMCs) Proliferation. *J. Cell Biochem*. 98, 1471–81.